FI117322B - Kemiallisesti määrättyjä valenssialustamolekyylejä ja menetelmä niiden konjugaattien valmistamiseksi - Google Patents

Kemiallisesti määrättyjä valenssialustamolekyylejä ja menetelmä niiden konjugaattien valmistamiseksi Download PDF

Info

Publication number
FI117322B
FI117322B FI961100A FI961100A FI117322B FI 117322 B FI117322 B FI 117322B FI 961100 A FI961100 A FI 961100A FI 961100 A FI961100 A FI 961100A FI 117322 B FI117322 B FI 117322B
Authority
FI
Finland
Prior art keywords
chemically defined
platform molecules
preparing conjugates
valence platform
defined valence
Prior art date
Application number
FI961100A
Other languages
English (en)
Swedish (sv)
Other versions
FI961100A (fi
FI961100A0 (fi
Inventor
Stephen M Coutts
David S Jones
Douglas Alan Livingston
Lin Yu
Original Assignee
Jolla Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/118,055 external-priority patent/US6060056A/en
Application filed by Jolla Pharma filed Critical Jolla Pharma
Publication of FI961100A0 publication Critical patent/FI961100A0/fi
Publication of FI961100A publication Critical patent/FI961100A/fi
Application granted granted Critical
Publication of FI117322B publication Critical patent/FI117322B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FI961100A 1993-09-08 1996-03-08 Kemiallisesti määrättyjä valenssialustamolekyylejä ja menetelmä niiden konjugaattien valmistamiseksi FI117322B (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/118,055 US6060056A (en) 1991-02-08 1993-09-08 Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule
US08/152,506 US5552391A (en) 1990-01-16 1993-11-15 Chemically-defined non-polymeric valency platform molecules and conjugates thereof
PCT/US1994/010031 WO1995007073A1 (en) 1993-09-08 1994-09-08 Chemically-defined non-polymeric valency platform molecules and conjugates thereof

Publications (3)

Publication Number Publication Date
FI961100A0 FI961100A0 (fi) 1996-03-08
FI961100A FI961100A (fi) 1996-05-08
FI117322B true FI117322B (fi) 2006-09-15

Family

ID=26815927

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961100A FI117322B (fi) 1993-09-08 1996-03-08 Kemiallisesti määrättyjä valenssialustamolekyylejä ja menetelmä niiden konjugaattien valmistamiseksi

Country Status (9)

Country Link
US (5) US5552391A (fi)
EP (1) EP0722318A4 (fi)
JP (2) JPH09500389A (fi)
CN (2) CN1203847C (fi)
AU (1) AU677710B2 (fi)
CA (1) CA2171434C (fi)
FI (1) FI117322B (fi)
NO (1) NO319084B1 (fi)
WO (1) WO1995007073A1 (fi)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5268454A (en) * 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
DK0642798T3 (da) * 1993-09-08 2007-09-10 Jolla Pharma Kemisk definerede, ikke polymere valensplatformmolekyler og konjugater deraf
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US5874409A (en) * 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US6410775B1 (en) * 1995-06-07 2002-06-25 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
CA2256449A1 (en) * 1996-06-06 1997-12-11 Lajolla Pharmaceutical Company Apl immunoreactive peptides, conjugates thereof and methods of treatment for apl antibody-mediated pathologies
US6759509B1 (en) * 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
EP0949782B1 (en) 1998-03-13 2015-06-17 Canon Kabushiki Kaisha Information processing apparatus and method
US6251382B1 (en) * 1998-04-17 2001-06-26 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
EP1632496A1 (en) * 1998-06-22 2006-03-08 Affymetrix, Inc. Reagents and methods for solid phase synthesis and display
US6399578B1 (en) * 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
CA2353462A1 (en) * 1998-12-09 2000-06-15 La Jolla Pharmaceutical Company Molecular scaffolds acting as templates comprising carbamate linkages
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US20010010818A1 (en) * 1998-12-09 2001-08-02 Engle Steven B. Methods and formulations for reducing circulating antibodies
CA2353620A1 (en) * 1998-12-09 2000-06-15 La Jolla Pharmaceutical Company Methods and formulations for reducing circulating antibodies
EP1183230A1 (en) * 1999-06-08 2002-03-06 La Jolla Pharmaceutical Valency platform molecules comprising aminooxy groups
CA2380947C (en) * 1999-08-19 2011-11-01 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
WO2001041813A2 (en) 1999-11-28 2001-06-14 La Jolla Pharmaceutical Company Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
CN1434726A (zh) * 2000-06-08 2003-08-06 拉卓拉药物公司 包含高分子量聚环氧乙烷的多价平台分子
AU9630501A (en) * 2000-09-26 2002-04-08 Univ Duke Rna aptamers and methods for identifying the same
ATE471374T1 (de) * 2000-12-27 2010-07-15 Dynavax Tech Corp Immunomodulatorische polynukleotide und verfahren zur deren verwendung
JP2004530736A (ja) * 2001-02-20 2004-10-07 エンゾン ファーマシューティカルズ，インコーポレーテッド 末端分枝高分子リンカーおよびそれを含む高分子複合体
MXPA03007392A (es) * 2001-02-20 2003-12-04 Enzon Inc Enlazantes polimericos ramificados terminalmente y conjugados polimericos que contienen los mismos.
WO2002092011A2 (en) * 2001-05-17 2002-11-21 La Jolla Pharmaceutical Company Methods of treating antibody-mediated pathologies using agents which inhibit cd21
ES2474192T3 (es) * 2001-05-25 2014-07-08 Duke University Moduladores de agentes farmacol�gicos
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
CN100334228C (zh) 2001-06-21 2007-08-29 戴纳瓦克斯技术公司 嵌合免疫调制化合物及其使用方法
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
US20030138425A1 (en) * 2001-09-21 2003-07-24 Mather Jennie Powell Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
GB0123961D0 (en) * 2001-10-05 2001-11-28 Astrazeneca Ab Process and intermediates
US7105135B2 (en) * 2001-10-16 2006-09-12 Lockheed Martin Corporation System and method for large scale detection of hazardous materials in the mail or in other objects
EP1492870A4 (en) * 2002-04-12 2005-08-03 Raven Biotechnologies Inc ANTIBODIES BINDING TO INTEGRIN-ALPHA-V-BETA-6 AND METHOD OF USE THEREOF
US20040048319A1 (en) * 2002-05-03 2004-03-11 Mather Jennie P. ALCAM and ALCAM modulators
PT1565489E (pt) * 2002-06-19 2011-02-23 Raven Biotechnologies Inc Anticorpos internalizantes específicos para o alvo de superfície celular raag10
AU2003259827B2 (en) 2002-08-12 2008-09-04 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
US7405061B2 (en) * 2002-11-13 2008-07-29 Raven Biotechnologies, Inc. Antigen PIPA and antibodies that bind thereto
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
EP1992635B1 (en) 2002-12-23 2012-02-08 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US20040208864A1 (en) * 2002-12-27 2004-10-21 Vibeke Strand Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
WO2004089422A2 (en) * 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals
CN1279056C (zh) * 2003-06-06 2006-10-11 马菁 肿瘤相关抗原sm5－1的特异性抗体及其应用
US20050232926A1 (en) * 2003-06-06 2005-10-20 Oncomax Acquisition Corp. Antibodies specific for cancer associated antigen SM5-1 and uses thereof
WO2005023844A1 (ja) * 2003-09-03 2005-03-17 Kyowa Hakko Kogyo Co., Ltd. グリセロール誘導体で修飾された化合物
BRPI0414513A (pt) 2003-09-18 2007-01-02 Raven Biotechnologies Inc kid3 e anticorpos de kid3 que se ligam a ele
CN103045601B (zh) * 2004-04-22 2015-04-01 雷加多生物科学公司 改良的凝血因子调节物
EP1765868B1 (en) * 2004-06-07 2016-04-20 MacroGenics, Inc. Transferrin receptor antibodies
NZ553581A (en) 2004-09-01 2011-04-29 Dynavax Tech Corp Methods and compositions for inhibition of innate immune responses and autoimmunity using immunoregulatory polynucleotides with a TGC sequence
EP1836218A2 (en) * 2004-12-17 2007-09-26 Dynavax Technologies Corporation Methods and compositions for induction or promotion of immune tolerance
US7687242B2 (en) * 2005-01-12 2010-03-30 Raven Biotechnologies, Inc. KID31 and antibodies that bind thereto
US7847070B2 (en) * 2005-01-31 2010-12-07 Raven Biotechnologies, Inc. LUCA2 and antibodies that bind thereto
WO2006084078A2 (en) * 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Jam-3 and antibodies that bind thereto
MX2007009222A (es) 2005-02-02 2008-01-16 Raven Biotechnologies Inc Moduladores de adam-9.
US7572896B2 (en) 2005-02-03 2009-08-11 Raven Biotechnologies, Inc. Antibodies to oncostatin M receptor
CN104059150B (zh) * 2005-02-04 2018-10-02 宏观基因有限公司 结合epha2的抗体及其使用方法
CA2668800A1 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
EP2094849B1 (en) * 2006-11-09 2014-01-08 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
JP5749492B2 (ja) 2007-10-26 2015-07-15 ダイナバックス テクノロジーズ コーポレイション 免疫応答と自己免疫を阻害する方法及び組成物
WO2009140626A2 (en) 2008-05-15 2009-11-19 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
WO2011020024A2 (en) 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
ES2560809T3 (es) * 2010-02-12 2016-02-22 Yeda Research And Development Co. Ltd. Diagnóstico de lupus eritematoso sistémico
CA2791658C (en) 2010-03-04 2019-10-01 Macrogenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
KR101810593B1 (ko) 2010-06-16 2017-12-22 다이나박스 테크놀로지 코퍼레이션 Ｔｌｒ7 및／또는 ｔｌｒ9 억제제를 사용하는 치료 방법
US9228184B2 (en) 2012-09-29 2016-01-05 Dynavax Technologies Corporation Human toll-like receptor inhibitors and methods of use thereof
JP2017503169A (ja) 2013-12-31 2017-01-26 イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド オリゴヌクレオチド抗原を使用する全身性エリテマトーデスの診断
CN106604740A (zh) 2014-02-14 2017-04-26 宏观基因有限公司 用于治疗血管化癌症的改进的方法
CN107533058A (zh) 2015-03-01 2018-01-02 免疫阵列有限公司 使用蛋白、肽和寡核苷酸抗原诊断系统性红斑狼疮
US10864279B2 (en) 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
US11198761B2 (en) * 2017-02-16 2021-12-14 Agency For Science, Technology And Research Biodegradable polyionenes
JP7234349B2 (ja) * 2018-05-04 2023-03-07 ツインピッグバイオラブ インク． メリチンベースのアポトシース促進ペプチドペプチドでｍ２様腫瘍関連マクロファージの標的化
GB201909103D0 (en) * 2019-06-25 2019-08-07 Univ Bath Compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4191668A (en) * 1977-02-03 1980-03-04 Scripps Clinic And Research Foundation Induction of immunological tolerance
US4220565A (en) * 1979-01-18 1980-09-02 Scripps Clinic & Research Foundation Immunochemical conjugates: method and composition
US5126131A (en) * 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
EP0229108B1 (en) * 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4946235A (en) * 1989-10-11 1990-08-07 Eastman Kodak Company Nonlinear optical waveguide device
US5162515A (en) * 1990-01-16 1992-11-10 La Jolla Pharmaceutical Company Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
CA2098281A1 (en) * 1990-12-17 1992-06-18 Howard M. Dintzis Suppression of immune responses of oligomeric forms of antigen of controlled chemistry
WO1993012145A1 (en) * 1991-12-19 1993-06-24 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
DK0642798T3 (da) * 1993-09-08 2007-09-10 Jolla Pharma Kemisk definerede, ikke polymere valensplatformmolekyler og konjugater deraf

Also Published As

Publication number Publication date
WO1995007073A1 (en) 1995-03-16
CN1572797A (zh) 2005-02-02
US20080293660A1 (en) 2008-11-27
JPH09500389A (ja) 1997-01-14
CN1318023C (zh) 2007-05-30
FI961100A (fi) 1996-05-08
US5552391A (en) 1996-09-03
NO960952D0 (no) 1996-03-07
US20070254851A1 (en) 2007-11-01
CN1203847C (zh) 2005-06-01
CA2171434A1 (en) 1995-03-16
NO319084B1 (no) 2005-06-13
JP2002085062A (ja) 2002-03-26
US5606047A (en) 1997-02-25
CN1134109A (zh) 1996-10-23
AU7720994A (en) 1995-03-27
AU677710B2 (en) 1997-05-01
FI961100A0 (fi) 1996-03-08
CA2171434C (en) 2009-03-17
NO960952L (no) 1996-05-02
EP0722318A4 (en) 1998-08-05
US5633395A (en) 1997-05-27
EP0722318A1 (en) 1996-07-24

Similar Documents

Publication Publication Date Title
FI117322B (fi) Kemiallisesti määrättyjä valenssialustamolekyylejä ja menetelmä niiden konjugaattien valmistamiseksi
FI941137A0 (fi) 2-debentsoyyli-2-asyylitaksolijohdannaisia ja menetelmiä niiden valmistamiseksi
FI963254A (fi) Alifaattinen polyesterihartsi ja menetelmä sen valmistamiseksi
FI96961B (fi) Biorientoitu kalvo, menetelmä sen valmistamiseksi ja sen käyttö
FI945374A0 (fi) Polymeerien liuotusmenetelmä ja -laite
FI955478A0 (fi) Menetelmä ja laite suulakepuristuskyllästämistä varten
FI942546A0 (fi) Menetelmä hienojakoisten ja muunnettujen tärkkelyksien valmistamiseksi
FI964310A0 (fi) Imidatsolijohdannainen ja menetelmä sen valmistamiseksi
FI941914A0 (fi) 2-amino-4-kinoliinidihydropyridiinejä, menetelmiä niiden valmistamiseksi ja niiden käyttö
FI923855A (fi) Katalysaattori ja sen valmistusmenetelmä
FI955123A0 (fi) Kolestyramiinia sisältävä koostumus ja menetelmä tämän valmistamiseksi
FI941414A0 (fi) Menetelmä ja laitteisto bioproteiinien valmistamiseksi
FI944842A0 (fi) Fluoratut 4-aminoandrostadienonijohdannaiset ja menetelmä niiden valmistamiseksi
FI942046A (fi) Polysykliset yhdisteet ja menetelmä niiden valmistamiseksi
FI950829A (fi) Kuitumateriaali ja menetelmä sen valmistamiseksi
FI98502B (fi) Puuperäiset muotokappaleet ja menetelmä niiden valmistamiseksi
FI940403A0 (fi) Elliptisiinijohdannainen ja menetelmä sen valmistamiseksi
FI904504A0 (fi) Menetelmä ja laite taitettujen painotuotteiden puristamiseksi
FI935715A (fi) Menetelmä sennosidien A ja B valmistamiseksi
FI921197A (fi) Platinaa säästävä katalyytti ja menetelmä sen valmistamiseksi
FI954769A (fi) Menetelmä ja laite prosessivalvontaa varten
FI88853C (fi) Foerfarande och anordning foer skogsgallring
FI102030B1 (fi) Menetelmä keratiinipitoista materiaalia sisältävän rehuraaka-aineen valmistamiseksi, rehuraaka-aine ja laite keratiinipitoisen materiaalin käsittelemiseksi
FI91543B (fi) Menetelmä ja laite ferrokromin valmistamiseksi
FI945249A (fi) Muovinauha ja menetelmä sen valmistamiseksi

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117322

Country of ref document: FI